Revisiting PPARγ as a new friend of GPR120 in the treatment of metabolic disorders

Vivian A. Paschoal, Da Young Oh

Research output: Contribution to journalReview articlepeer-review

Abstract

G Protein-coupled receptor 120 (GPR120; fatty acid receptor 4, FFAR4) and PPARγ agonists both lead to anti-inflammatory and insulin sensitizing effects despite signalling through distinct pathways. We recently reported the overarching idea that these two pathways are interactive. Specifically, treatment of obese mice with the PPARγ agonist rosiglitazone (a thiazolidinedione, TZD) in combination with the GPR120 agonist compound A synergistically improves glucose tolerance and insulin sensitivity. We have deconvoluted the mechanisms underlying this feed-forward effect in the study. Taken together, our study shows that low dose TZD administration, in combination with GPR120 agonists, produces additive beneficial effects on glucose tolerance and insulin sensitivity without the undesirable adverse effects of TZD. Our study suggests potential value of combination PPARγ and GPR120 agonists to treat metabolic disease.

Original languageEnglish (US)
Pages (from-to)649-652
Number of pages4
JournalAdipocyte
Volume9
Issue number1
DOIs
StatePublished - Jan 1 2020

Keywords

  • GPR120
  • PPAR gamma
  • insulin resistance
  • metabolism
  • type 2 diabetes

ASJC Scopus subject areas

  • Histology
  • Cell Biology

Fingerprint Dive into the research topics of 'Revisiting PPARγ as a new friend of GPR120 in the treatment of metabolic disorders'. Together they form a unique fingerprint.

Cite this